REG - Destiny Pharma PLC - Grant of Share Options
12/05/2023 12:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230512:nRSL2856Za&default-theme=true
RNS Number : 2856Z Destiny Pharma PLC 12 May 2023
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Grant of Share Options
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology
company focused on the development of novel medicines that can prevent
life-threatening infections, announces that it has granted options over a
total of 431,354 new ordinary shares of £0.01 each in the Company ("Options")
(representing 0.45 per cent. of the Company's issued share capital) to certain
employees of the Company, including the Directors and PDMR named below.
Name Position Deferred Bonus Options issued Total Options Options Ordinary Shares held Ordinary Shares held as a percentage
Under 2020 LTIP held held as a percentage of issued share capital of issued share capital
Scheme* post issue
Neil Clark Chief Executive Officer 52,264 1,424,798 1.50% 117,033 0.12%
Shaun Claydon Chief Financial Officer 47,100 911,001 0.96% 24,286 0.03%
William Love** Chief Scientific Officer 43,313 959,549 1.01% 6,509,500 6.83%
Yuri Martina Chief Medical Officer 71,177 261,177 0.27% - -
* granted in respect of bonuses due for the financial year ended 31
December 2022
**3,317,700 of these Ordinary Shares are held by William Love and 3,191,800
are held by Carol Love
The above options granted to the Directors and PDMR represent awards granted
under the Destiny Pharma plc 2020 Long Term Incentive Plan approved by the
Company on 22 December 2020 for EMI and non-tax advantaged options (the
"Employee LTIP 2020"). The above options granted to the Directors and PDMR
have been granted with a nominal exercise price, will vest on 1 February 2025
and are exercisable up to 10 years from the date of grant. Including the grant
of these Options, the Company will have outstanding options over approximately
8.72 per cent. of its issued share capital.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0)20 7220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Optimum Strategic Communications
Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has completed a positive Phase 2 clinical trial targeting the prevention of
post-surgical staphylococcal hospital infections including MRSA. It is also
co-developing SPOR-COV(TM), a novel, biotherapeutic product for the prevention
of COVID-19 and other viral respiratory infections and has earlier grant
funded XF drug research projects.
For further information on the Company, please
visit https://www.destinypharma.com (https://www.destinypharma.com/)
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Neil Clark
2. Reason for the Notification
a) Position/status Chief Executive Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Destiny Pharma plc
b) LEI 213800O9WH9Z38EHAC95
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Grant of award of options over ordinary shares of 1 pence each ("Ordinary
Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
Identification code DEST GB00BDHSP575
b) Nature of the transaction Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma
plc Long Term Incentive Plan.
c) Price(s) and volume(s) 1 pence exercise price per Ordinary Share
52,264 Ordinary Shares
d) Aggregated information:
Aggregated volume See 4c) above
Price
e) Date of the transaction 12 May 2023
f) Place of the transaction Outside of trading venue
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Shaun Claydon
2. Reason for the Notification
a) Position/status Chief Financial Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Destiny Pharma plc
b) LEI 213800O9WH9Z38EHAC95
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Grant of award of options over ordinary shares of 1 pence each ("Ordinary
Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
Identification code DEST GB00BDHSP575
b) Nature of the transaction Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma
plc Long Term Incentive Plan.
c) Price(s) and volume(s) 1 pence exercise price per Ordinary Share
47,100 Ordinary Shares
d) Aggregated information:
Aggregated volume See 4c) above
Price
e) Date of the transaction 12 May 2023
f) Place of the transaction Outside of trading venue
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name William Love
2. Reason for the Notification
a) Position/status Chief Scientific Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Destiny Pharma plc
b) LEI 213800O9WH9Z38EHAC95
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Grant of award of options over ordinary shares of 1 pence each ("Ordinary
Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
Identification code DEST GB00BDHSP575
b) Nature of the transaction Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma
plc Long Term Incentive Plan.
c) Price(s) and volume(s) 1 pence exercise price per Ordinary Share
43,313 Ordinary Shares
d) Aggregated information:
Aggregated volume See 4c) above
Price
e) Date of the transaction 12 May 2023
f) Place of the transaction Outside of trading venue
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Yuri Martina
2. Reason for the Notification
a) Position/status Chief Medical Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Destiny Pharma plc
b) LEI 213800O9WH9Z38EHAC95
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Grant of award of options over ordinary shares of 1 pence each ("Ordinary
Shares") the 2020 Destiny Pharma plc Long Term Incentive Plan.
Identification code DEST GB00BDHSP575
b) Nature of the transaction Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma
plc Long Term Incentive Plan.
c) Price(s) and volume(s) 1 pence exercise price per Ordinary Share
71,177 Ordinary Shares
d) Aggregated information:
Aggregated volume See 4c) above
Price
e) Date of the transaction 12 May 2023
f) Place of the transaction Outside of trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHATMBTMTTBBIJRecent news on Destiny Pharma
See all newsRCS - Destiny Pharma PLC - FDA grants XF-73 Dermal QIPD for burn wound
AnnouncementRCS - Destiny Pharma PLC - Presentation at ESCMID on XF-73 Nasal Gel
AnnouncementRCS - Destiny Pharma PLC - Exploration of XF drug potential for CF
AnnouncementREG - AIM Destiny Pharma PLC - Cancellation - Destiny Pharma plc
AnnouncementREG - Destiny Pharma PLC - Last Day of Dealings on AIM
Announcement